
Watch closely. In one hand, we have imatinib—the drug that transformed chronic myeloid leukemia from a death sentence into a manageable condition back in 2001. Revolutionary stuff. In the other hand, we have the newer second-generation TKIs that promised even better results. And now, for the...


















